Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AtaiBeckley Inc. - Common Stock (NQ:ATAI)

7.350 UNCHANGED
Last Price Updated: 4:00 PM EDT, Sep 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about AtaiBeckley Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
atai Life Sciences Reports Third Quarter 2023 Financial Results and Pipeline Highlights
From atai Life Sciences
Via GlobeNewswire
News headline image
atai Life Sciences to Participate in the Jefferies Inaugural Biotech CNS/Neuro Summit
From atai Life Sciences
Via GlobeNewswire
News headline image
atai Life Sciences Announces Completion of Phase 1 Study of VLS-01 in Healthy Participants
From atai Life Sciences
Via GlobeNewswire
The Breakthrough Therapy Aiming To Solve The World’s Mental Health Crisis
EQNX::TICKER_START (NYSE:JNJ),(NYSE:ABBV),(NASDAQ:ATAI),(NASDAQ:CMPS),(NASDAQ:MNMD) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Economy
News headline image
atai Life Sciences to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference
From atai Life Sciences
Via GlobeNewswire
News headline image
atai Life Sciences to Participate in Upcoming September Investor Conferences
From atai Life Sciences
Via GlobeNewswire
News headline image
atai Life Sciences Reports Second Quarter 2023 Financial Results and Operational Highlights, and Announces Clinical Data from the Phase 1 Study of DMX-1002 (Ibogaine)
From atai Life Sciences
Via GlobeNewswire
News headline image
atai Life Sciences Announces Results from the Phase 1 IV-to-Subcutaneous Bridging Study of PCN-101 (R-Ketamine)
From atai Life Sciences
Via GlobeNewswire
News headline image
atai Life Sciences to Participate in Upcoming June Investor Conferences
From atai Life Sciences
Via GlobeNewswire
News headline image
atai Life Sciences Reports First Quarter 2023 Financial Results and Announces Pipeline Highlights and Updates
From atai Life Sciences
Via GlobeNewswire
News headline image
atai Life Sciences to Participate in Upcoming May Investor Conference
From atai Life Sciences
Via GlobeNewswire
News headline image
atai Life Sciences Presents Pharmacodynamic Data on GRX-917 in a Late Breaking Poster Presentation at the 2023 SOBP Annual Meeting
From atai Life Sciences
Via GlobeNewswire
News headline image
atai Life Sciences Announces First Subject Dosed in the Phase 1 IV-to-Subcutaneous Bridging Study of PCN-101 (R-Ketamine)
From atai Life Sciences
Via GlobeNewswire
News headline image
atai Life Sciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Pipeline Highlights
From atai Life Sciences
Via GlobeNewswire
News headline image
atai Life Sciences Announces Key Clinical Pipeline and Corporate Updates
From atai Life Sciences
Via GlobeNewswire
News headline image
atai Life Sciences to Participate in the Cowen 43rd Annual Health Care Conference
From atai Life Sciences
Via GlobeNewswire
Psychedelic-Derived Medicines for Neurologic Conditions Fueling Large Revenue Growth in Projected $4 Billion Dollar Industry
EQNX::TICKER_START (OTCQB:LOBEF),(NASDAQ:ATAI),(NASDAQ:CMPS),(NYSE:CYBN),(NASDAQ:MNMD) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Economy
News headline image
atai Life Sciences Company GABA Therapeutics Announces Positive Final Results from Phase 1 Single and Multiple Ascending Dose Trial of GRX-917
From atai Life Sciences
Via GlobeNewswire
News headline image
atai Life Sciences Announces Results from Phase 2a Trial of PCN-101 (R-ketamine) for Treatment-Resistant Depression
From atai Life Sciences
Via GlobeNewswire
News headline image
atai Life Sciences Announces Results from the Kures Therapeutics Phase 1 Trial of KUR-101
From atai Life Sciences
Via GlobeNewswire
News headline image
atai Life Sciences Initiates Phase 2b proof-of-concept trial of RL-007 for Cognitive Impairment Associated with Schizophrenia
From atai Life Sciences
Via GlobeNewswire
News headline image
The atai Fellowship Fund in Psychedelic Neuroscience Announces its First Cohort at Massachusetts General Hospital
From atai Life Sciences
Via GlobeNewswire
News headline image
atai Life Sciences Strengthens Leadership Team with Appointment of Dr. Sahil V. Kirpekar as Chief Business Officer
From atai Life Sciences
Via GlobeNewswire
News headline image
atai Life Sciences and Massachusetts General Hospital Announce Initiation of Clinical Study Investigating Neuroplasticity Biomarkers in Treatment-Resistant Depression Patients Undergoing Ketamine Treatment
From atai Life Sciences
Via GlobeNewswire
Greater Prevalence of Anxiety & Depressive Disorders Driving Demand for New Anti-Anxiety Drug Candidates
EQNX::TICKER_START (NASDAQ:SAGE),NASDAQ:NERV),(NASDAQ:ATAI),(NYSE:CYBN),(TSXV:MRVL),(NEO:CYBN), EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Retirement
News headline image
atai Life Sciences Reports Third Quarter 2022 Financial Results and Business Update
From atai Life Sciences
Via GlobeNewswire
News headline image
Women in Psychedelics Announces atai as Platinum Sponsors
From Women in Psychedelics Network
Via Business Wire
News headline image
atai Life Sciences to Participate in November Investor Events & Healthcare Conferences
From atai Life Sciences
Via GlobeNewswire
News headline image
atai Life Sciences to Announce Third Quarter 2022 Financial Results and Business Update
From atai Life Sciences
Via GlobeNewswire
News headline image
atai Life Sciences Company, Perception Neuroscience, Completes Enrollment for Phase 2a Clinical Trial of PCN-101 (R-Ketamine) for Treatment-Resistant Depression
From atai Life Sciences
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.